T-cell specific surface glycoprotein CD28 market is anticipated to grow at a significant CAGR during the forecast period. CD28 is a glycoprotein of 90 kDa and occurs naturally as a disulfide-linked homodimer of a polypeptide that contains a single Ig-like extracellular domain. Additionally, it is a member of the Ig superfamily and is expressed on T cells that provide co-stimulatory signals which are required for T cell activation and survival. Furthermore, it acts as a major costimulation pathway for naive T-cell activation while playing a central role in immune responses against pathogens, autoimmune diseases, and graft rejection.
Moreover, it enhances the production of IL4 and IL10 in T-cells in conjunction. Additionally, it signals the initial activation of naive CD4 T cells by increasing the sensitivity of the T cell to antigen receptor engagement. Furthermore, CD28 is expressed on 50% of CD8+ T cells and more than 80% CD4+ T cells in humans and supports to kill cancer cells that are virally infected or that are under damage. Hence, the factor driving the growth of the market is the prevalence of cancer.
According to the National Cancer Institute (NCI), it was estimated that 1,806,590 new cases of cancer will be diagnosed in the US in 2020. Furthermore, there were 18.1 million new cases and 9.5 million cancer-related mortalities globally in 2018 which is anticipated to rise to 29.5 million and the number of cancer-related mortalities to 16.4 million by 2040. Some major players in the market include Bristol-Myers Squibb Co., and Johnson and Johnson Services, Inc., among others.
To Request a Sample of our Report on T-Cell Specific Surface Glycoprotein CD28 Market: https://www.omrglobal.com/request-sample/t-cell-specific-surface-glycoprotein-cd28-market
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Amgen Inc., and Johnson & Johnson Services, Inc., among others.
T-Cell Specific Surface Glycoprotein CD28 Market Report by Segment
By Type
- FPT-155
- FR-104
- Lulizumab Pegol
- Others
By Application
- Plaque Psoriasis
- Solid Tumor
- Acute Renal Failiure(ARF)
- Others
A full Report of T-Cell Specific Surface Glycoprotein CD28 Market is Available @ https://www.omrglobal.com/industry-reports/t-cell-specific-surface-glycoprotein-cd28-market
T-Cell Specific Surface Glycoprotein CD28 Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
